Financial PerformanceNet loss was $18.8M, or ($0.49) per share, moderately higher than estimated, indicating financial strain.
Funding RequirementsThe company may need to raise additional capital, indicating potential financial challenges ahead.
Regulatory And Commercial RisksRisks include failure of product candidates in clinical trials, failure to secure regulatory approval, and potential dilution risk, impacting future valuation.